Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam

BACKGROUND: Ceftolozane/tazobactam (C/T) efficacy and safety in ventilator-associated pneumonia (VAP) is being evaluated at a double dose by several trials. This dosing is based on a pharmacokinetic (PK) model that demonstrated that 3 g q8h achieved ≥90% probability of target attainment (50% ƒT >...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Núñez, Olga, Periañez-Parraga, Leonor, Oliver, Antonio, Munita, Jose M, Boté, Anna, Gasch, Oriol, Nuvials, Xavier, Dinh, Aurélien, Shaw, Robert, Lomas, Jose M, Torres, Vicente, Castón, Juanjo, Araos, Rafael, Abbo, Lilian M, Rakita, Robert, Pérez, Federico, Aitken, Samuel L, Arias, Cesar A, Martín-Pena, M Luisa, Colomar, Asun, Núñez, M Belén, Mensa, Josep, Martínez, José Antonio, Soriano, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810667/
https://www.ncbi.nlm.nih.gov/pubmed/31660373
http://dx.doi.org/10.1093/ofid/ofz416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810667/
https://www.ncbi.nlm.nih.gov/pubmed/31660373
http://dx.doi.org/10.1093/ofid/ofz416

Ejemplares similares